ZymoGenetics
Former biotechnology company From Wikipedia, the free encyclopedia
ZymoGenetics, Inc was one of the oldest biotechnology/pharmaceutical companies in the USA,[1] based in Seattle, Washington. The company was involved in the development of therapeutic proteins. Located on Lake Union, the address of the ZymoGenetics headquarters was 1201 Eastlake Avenue East.[2] It was closed in 2019 after its acquisition by Bristol Myers Squibb.[3][4]
 | |
| Company type | Public |
|---|---|
| Industry | Biotechnology/Pharmaceuticals |
| Founded | 1981 in Seattle, Washington |
| Founders | Earl W. Davie, Michael Smith and Benjamin D. Hall |
| Headquarters | Lake Union Steam Plant Building, 1201 Eastlake Avenue East, Seattle , Washington, USA |
Key people | Stephanie Feldt |
| Products | Pharmaceuticals |
| Owner | Bristol-Myers Squibb |
| Website | Archived website |
The company was founded in 1981[5] by Professors Earl W. Davie and Benjamin D. Hall of the University of Washington and 1993 Nobel Laureate in Chemistry Michael Smith of the University of British Columbia.[2] Initially named Zymos,[6] the company was forced to change its name to ZymoGenetics under threat of trademark infringement from the similarly named semiconductor company ZyMOS.[7] Soon after its founding, ZymoGenetics began working on recombinant proteins with Danish company Novo Nordisk, and was acquired by that company in 1988.[8] It was spun off as a public company in 2000.[1] Bristol-Myers Squibb acquired the company in 2010 for $885 million.[9][10]
ZymoGenetics' headquarters was previously in the landmark Lake Union Steam Plant building.[11] This structure was built from 1914 to 1921 by Seattle City Light, the municipal electric utility.[12] At the time, the building was in poor condition with many broken windows; Bruce Carter, the chief executive at the time, described it as "the mother of all fixer-uppers".[13] In December 2016, ZymoGenetics announced that they would not renew the lease to the Steam Plant building, due to expire in 2019;[14] the Fred Hutchinson Cancer Research Center later moved into it.[15] At the time, ZymoGenetics did not plan on closing its Bothell manufacturing site;[14] however, it was sold to Seattle Genetics in August 2017.[16] ZymoGenetics closed completely in 2019.[3][4]
Corporate governance
In late 2013, the company's president, Stephen W. Zaruby, left and took up the president and chief executive officer roles at Aurinia Pharmaceuticals.[17]
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.